Cargando…
Cardiac safety analysis of anti-HER2-targeted therapy in early breast cancer
To evaluate the cardiac safety of anti-HER2-targeted therapy for early breast cancer; to investigate whether trastuzumab combined with pertuzumab increases cardiac toxicity compared with trastuzumab; to evaluate the predictive value of high-sensitivity Troponin (hs-TnI) and QTc for the cardiotoxicit...
Autores principales: | Zhang, Li, Wang, Yan, Meng, Wenjing, Zhao, Weipeng, Tong, Zhongsheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9395410/ https://www.ncbi.nlm.nih.gov/pubmed/35995984 http://dx.doi.org/10.1038/s41598-022-18342-1 |
Ejemplares similares
-
Real‐world data for the renal safety of abemaciclib combined with bisphosphonate in HR+/HER2− advanced breast cancer
por: Hao, Chunfang, et al.
Publicado: (2022) -
Construction of differentially expressed Her-2 related lncRNA-mRNA-miRNA ceRNA network in Her-2 positive breast cancer
por: Jia, Xiaochen, et al.
Publicado: (2020) -
Analysis of Clinical Characteristics, Treatment, and Prognostic Factors of 106 Breast Cancer Patients With Solitary Pulmonary Nodules
por: He, Lihong, et al.
Publicado: (2022) -
Efficacy and Safety of Anti-HER2 Targeted Therapy for Metastatic HR-Positive and HER2-Positive Breast Cancer: A Bayesian Network Meta-Analysis
por: Wu, Xian-Meng, et al.
Publicado: (2023) -
Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial
por: de Azambuja, E., et al.
Publicado: (2023)